Showing 2391-2400 of 5623 results for "".
- Study: Warning Signs of Sight Loss Could be Identified Before Vision Deteriorateshttps://modernod.com/news/study-warning-signs-of-sight-loss-could-be-identified-before-vision-deteriorates/2480502/A new study has shown that the signs of age related macular degeneration can set in earlier than previously thought – even before patients begin to lose their sight. The findings open the door for research into earlier treatment that could help slow down the onset of the condition the most
- Treehouse Eyes Partners with J&J Vision to Deliver Treatment Innovation for Myopia Management: Acuvue Abiliti Overnight Therapeutic Lenseshttps://modernod.com/news/treehouse-eyes-partners-with-jj-vision-to-deliver-treatment-innovation-for-myopia-management-acuvue-abiliti-overnight-therapeutic-lenses/2480497/Treehouse Eyes, a health care business dedicated exclusively to treating myopic chi
- Ocular Therapeutix Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-topline-results-for-phase-2-clinical-trial-of-otx-ded-for-the-short-term-treatment-of-dry-eye-disease/2480496/Ocular Therapeutix announced positive topline results from its phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The phase 2 clinical trial is a US-based, randomized, double-masked, vehicle-controlled, m
- Amydis Has Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALShttps://modernod.com/news/amydis-has-pre-ind-meeting-with-the-fda-for-the-development-of-a-first-in-class-retinal-tracer-targeting-tdp43-for-the-diagnosis-of-als/2480493/Amydis announced the successful completion of a pre-IND (investigational new drug) meeting with the FDA regarding the development plans for a small-molecule tracer to detect TDP43 in the retina of amyotrophic lateral sclerosis (ALS) patients. The FDA agreed with the overall d
- Omeros to Sell Omidria Franchise to Rayner in a Deal Worth More Than $1 Billionhttps://modernod.com/news/omeros-to-sell-omidria-franchise-to-rayner-in-a-deal-worth-more-than-1-billion/2480488/Omeros announced that it has entered into a definitive agreement for the sale of Omidria to Rayner Surgical Group. The transaction, which is expected to close on or before December 31, 2021, includes an upfront payment of $125 million with an additional $200 million in
- LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platformhttps://modernod.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441. "This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,&
- Kubota Vision Announces Publication in Scientific Reports of Study Data for Wearable Myopia-Control Devicehttps://modernod.com/news/kubota-vision-announces-publication-in-scientific-reports-of-study-data-for-wearable-myopia-control-device/2480478/Kubota Vision announced the publication of a new paper in the journal Scientific Reports: Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel “press-on” lenses in humans. The paper
- Heidelberg Engineering Receives European Acceptance for Spectralis Shift Technology Under New Medical Device Regulationhttps://modernod.com/news/heidelberg-engineering-receives-european-acceptance-for-spectralis-shift-technology-under-new-medical-device-regulation/2480442/Heidelberg Engineering announced the launch of the Spectralis platform with shift technology, which is designed to create synergies that significantly increase efficiency in both OCT and OCTA, and deliver images with more detail. Shift enables clinicians to switch between OCT scan
- CORD LLC Completes One-Year Follow-Up on Subjects From the Model SC9 Intraocular Lens FDA Clinical Trialhttps://modernod.com/news/cord-llc-completes-one-year-follow-up-on-subjects-from-the-model-sc9-intraocular-lens-fda-clinical-trial/2480435/Cumming Ophthalmic Research and Development
- EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategyhttps://modernod.com/news/eyegate-is-now-kiora-pharmaceuticals-provides-update-on-companys-sharpened-clinical-development-strategy/2480411/Kiora Pharmaceuticals is the new name of EyeGate Pharmaceuticals. The new brand reflects the company’s aim to not only treat common eye conditions, but to develop a small molecule therapy for retinitis pigmentosa. Kiora will trade on the Nasdaq